{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:27Z","timestamp":1792004367750,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"RFU"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the in vitro activity of cefepime in association with a \u03b2-lactamase inhibitor (enmetazobactam) or \u03b2-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to sulbactam\/durlobactam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Twenty-one CRAB clinical isolates were characterized by WGS and AST to cefepime\/enmetazobactam, cefepime\/zidebactam and comparators was determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Resistome analysis revealed that all CRAB carried blaOXA-23 carbapenemase genes, while blaADC-25 and blaOXA-66 \u03b2-lactamase genes were observed exclusively in sulbactam\/durlobactam-resistant strains. Analysis of penicillin-binding protein genes demonstrated the presence of specific mutations within PBP3 (N392T) previously associated to the resistance to sulbactam\/durlobactam. Phenotypic analysis revealed that cefepime\/enmetazobactam did not exert antibacterial activity against CRAB, while cefepime\/zidebactam displayed potent bactericidal activity against both sulbactam\/durlobactam-susceptible and -resistant strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results demonstrate that cefepime\/zidebactam exhibited potent in vitro antibacterial activity against CRAB producing OXA carbapenemase and support its clinical use against both sulbactam\/durlobactam-susceptible or -resistant isolates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf467","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:00:08Z","timestamp":1765026008000},"source":"Crossref","is-referenced-by-count":4,"title":["<i>In vitro<\/i>\n                    activity of cefepime\/zidebactam against sulbactam\/durlobactam-susceptible and -resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    clinical isolates"],"prefix":"10.1093","volume":"81","author":[{"given":"Carlo","family":"Tascini","sequence":"first","affiliation":[{"name":"Department of Medicine, Universit\u00e0 degli Studi di Udine , Udine ,","place":["Italy"]},{"name":"Infectious Diseases Unit, Azienda Sanitaria Universitaria Friuli Centrale , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-5075","authenticated-orcid":false,"given":"Gabriele","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Salento , Lecce ,","place":["Italy"]},{"name":"Microbiology and Virology Unit, Vito Fazzi Hospital , Lecce ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University , Cleveland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-8635","authenticated-orcid":false,"given":"Paolo","family":"Gaibani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Public Health, Microbiology Section, Verona University , Verona ,","place":["Italy"]},{"name":"Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Di Verona , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902093386400_dkaf467-B1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/CCM.0000000000000125","article-title":"Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients","volume":"42","author":"Lee","year":"2014","journal-title":"Crit Care Med"},{"key":"2026011902093386400_dkaf467-B2","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/v15091934","article-title":"Prevalence and impact on mortality of colonization and super-infection by carbapenem-resistant Gram-negative organisms in COVID-19 hospitalized patients","volume":"15","author":"Casale","year":"2023","journal-title":"Viruses"},{"key":"2026011902093386400_dkaf467-B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcimb.2017.00055","article-title":"Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options","volume":"7","author":"Lee","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2026011902093386400_dkaf467-B4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093386400_dkaf467-B5","author":"WHO 2024"},{"key":"2026011902093386400_dkaf467-B6","doi-asserted-by":"publisher","first-page":"e0106324","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093386400_dkaf467-B7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026011902093386400_dkaf467-B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093386400_dkaf467-B9","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/antibiotics11121793","article-title":"Acinetobacter baumannii resistance to sulbactam\/durlobactam: a systematic review","volume":"11","author":"Principe","year":"2022","journal-title":"Antibiotics"},{"key":"2026011902093386400_dkaf467-B10","doi-asserted-by":"publisher","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093386400_dkaf467-B11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/10600280241279904","article-title":"Cefepime-enmetazobactam: a drug review of a novel beta-lactam\/beta-lactamase inhibitor","volume":"59","author":"Lanier","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026011902093386400_dkaf467-B12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","author":"Boattini","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011902093386400_dkaf467-B13","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1021\/acs.jmedchem.8b00091","article-title":"Strategic approaches to overcome resistance against Gram-negative pathogens using \u03b2-lactamase inhibitors and \u03b2-lactam enhancers: activity of three novel diazabicyclooctanes WCK 5153, zidebactam (WCK 5107), and WCK 4234","volume":"61","author":"Papp-Wallace","year":"2018","journal-title":"J Med Chem"},{"key":"2026011902093386400_dkaf467-B14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10096-025-05121-9","article-title":"Genomic characterization of carbapenem-resistant Acinetobacter baumannii clinical strains resistant to sulbactam\/durlobactam from Italy","volume":"44","author":"Caiazzo","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011902093386400_dkaf467-B15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against \u2018problem\u2019 antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093386400_dkaf467-B16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/jac\/dkx050","article-title":"WCK 5222 (cefepime\/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant \u03b2-lactamases","volume":"72","author":"Sader","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093386400_dkaf467-B17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011902093386400_dkaf467-B18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020","volume":"55","author":"Liu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2026011902093386400_dkaf467-B19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmi.2025.03.012","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives\u2014author\u2019s response","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093386400_dkaf467-B20","doi-asserted-by":"publisher","first-page":"e01931-18","DOI":"10.1128\/AAC.01931-18","article-title":"In vivo efficacy of humanized WCK 5222 (cefepime-zidebactam) exposures against carbapenem-resistant Acinetobacter baumannii in the neutropenic thigh model","volume":"63","author":"Almarzoky Abuhussain","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf467\/66444088\/dkaf467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf467\/66444088\/dkaf467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:50Z","timestamp":1768806590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf467\/8429087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf467","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf467"}}